MediWound Ltd.
MDWDHealthcare|Biotechnology|IL
$14.25
+0.92 (+6.90%)
Tangible Book / Share
$2.77
Cash / Share
$2.74
Clinical Trials (15)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06568627 A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) | Venous Leg Ulcer (VLU) | P3 | Recruiting | 216 | RCT, Double-blind | EscharEx (EX-03), Placebo (Gel vehicle) |
| NCT05157763 A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma | Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma | P1P2 | Recruiting | 32 | Open-label | EscharEx 5% (EX-02 formulation) |
| NCT02148705 A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns | Thermal Burns | P3 | Completed | 175 | RCT, Single-blind | NexoBrid, Gel Vehicle |
| NCT02278718 A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care | Thermal Burns | P3 | Completed | 145 | RCT, Single-blind | NexoBrid |
| NCT00324311 Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care | Burn | P3 | Completed | 182 | RCT, Open-label | DGD |
| NCT03588130 A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers | Venous Leg Ulcer | P2 | Completed | 120 | RCT, Double-blind | EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC) |
| NCT02020746 Efficacy and Safety Study of EscharEx to Treat (Debride) Hard to Heal Wounds | Hard to Heal Wounds, Venous Leg Ulcers | P2 | Completed | 111 | RCT, Double-blind | EscharEx, Gel Vehicle |
| NCT00898521 Feasibility Study: Enzymatic Debridement in Patients With Partial Thickness Burns | Burn | P2 | Completed | 36 | Open-label | DGD |
| NCT01679678 A Study, Performed in Subjects With Post Traumatic-post Surgical ,Venus Insufficiency and Diabetic Hard to Heal/Chronic Wounds, to Evaluate the Safety and Efficacy of PolyHeal-2 Versus PolyHeal in Once Daily Regimen | Surgical Wound Dehiscence | P2 | Terminated | 15 | RCT, Double-blind | — |
| NCT06690177 Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU) | Venus Leg Ulcers | P2 | Not Yet Recruiting | 45 | RCT, Double-blind | EscharEx (EX-03), Placebo (Gel vehicle) |
| NCT04817228 A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers | Venous Leg Ulcer, Diabetic Foot Ulcer | P2 | Completed | 12 | Open-label | EscharEx (EX-02 formulation) |
| NCT07692178 An Open Label, Single Treatment, Single Arm, Multiple Dose Phase-2 Study to Evaluate the Pharmacokinetics, Safety, and Clinical Performance of EscharEx (EX-03) in Participants With Venous Leg Ulcers | Venous Leg Ulcer (VLU) | P2 | Not Yet Recruiting | 20 | Open-label | EX-03 |
| NCT01350700 Long Term Follow up of Scars Formation and Quality of Life Assessment Study | Scars Formation, Quality of Life | Completed | 148 | — | — | |
| NCT04040660 Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries | Thermal Burn | APPROVED_FOR_MARKETING | — | — | NexoBrid | |
| NCT01800981 Functionality Assessments in Patients (Adults and Children) Following Treatment With Debrase Compared to Standard of Care | Burns, Upper Extremity, Burns, Lower Extremity | Unknown | 53 | — | — |